All articles tagged with #ultragenyx
Shares of Ultragenyx and Mereo BioPharma plummeted after their Phase 3 trial for the brittle-bone disease treatment setrusumab failed to meet primary endpoints, despite secondary improvements in bone density, leading to significant market value losses and cautious outlooks from analysts.
Ultragenyx Pharmaceutical's experimental drug setrusumab for osteogenesis imperfecta failed to reduce fracture rates in late-stage studies, leading to a 43.5% drop in its stock price and potential discontinuation of the program, despite improvements in bone mineral density.
Ultragenyx and Mereo's late-stage clinical trial for a rare bone disease drug has failed, marking a significant setback for the development program.
The FDA has declined to approve Ultragenyx's gene therapy, highlighting ongoing challenges in biotech approvals, while other news includes AstraZeneca's promising hypertension drug and insights into FDA commissioner Marty Makary's initiatives.